Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Operating Leases: 2019-2024

Historic Operating Leases for UroGen Pharma (URGN) over the last 6 years, with Dec 2024 value amounting to $1.7 million.

  • UroGen Pharma's Operating Leases rose 501.83% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 501.83%. This contributed to the annual value of $1.7 million for FY2024, which is 95.85% up from last year.
  • Per UroGen Pharma's latest filing, its Operating Leases stood at $1.7 million for FY2024, which was up 95.85% from $844,000 recorded in FY2023.
  • UroGen Pharma's 5-year Operating Leases high stood at $2.5 million for FY2022, and its period low was $398,000 during FY2021.
  • Its 3-year average for Operating Leases is $1.7 million, with a median of $1.7 million in 2024.
  • Its Operating Leases has fluctuated over the past 5 years, first crashed by 73.41% in 2021, then spiked by 534.92% in 2022.
  • Yearly analysis of 5 years shows UroGen Pharma's Operating Leases stood at $1.5 million in 2020, then plummeted by 73.41% to $398,000 in 2021, then spiked by 534.92% to $2.5 million in 2022, then slumped by 66.60% to $844,000 in 2023, then surged by 95.85% to $1.7 million in 2024.